Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis
JAMA Dermatology, 2023.
Ali Al-Janabi; Oras A. Alabas; Zenas Z. N. Yiu; Amy C. Foulkes; Steve Eyre; Adnan R. Khan; Nick J. Reynolds; Catherine H. Smith; Christopher E. M. Griffiths; Richard B. Warren; the BADBIR Study Group.
Read publication: JAMA Dermatology
Related
Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation stu...
Application of information theoretic feature selection and machine learning methods for the developm...
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the Br...
0 Comments